常山药业12月29日获融资买入7922.24万元，融资余额26.28亿元

Group 1 - The core viewpoint of the news is that Changshan Pharmaceutical's stock has experienced a decline, with significant trading activity and high financing levels, indicating potential investor concerns [1][2] - On December 29, Changshan Pharmaceutical's stock fell by 2.39%, with a trading volume of 743 million yuan. The net financing buy was negative at 1.09 million yuan, with a total financing balance of 2.628 billion yuan, accounting for 4.63% of the circulating market value [1] - The company has a high financing balance that exceeds the 90th percentile of the past year, indicating elevated levels of investor leverage [1] Group 2 - As of December 19, the number of shareholders in Changshan Pharmaceutical decreased by 4.57% to 39,600, while the average circulating shares per person increased by 4.79% to 23,203 shares [2] - For the period from January to September 2025, Changshan Pharmaceutical reported a revenue of 681 million yuan, a year-on-year decrease of 13.11%, and a net profit attributable to shareholders of -44.82 million yuan, a decline of 714.77% [2] - The company has distributed a total of 181 million yuan in dividends since its A-share listing, with 4.595 million yuan distributed over the last three years [3]